

Securities Code: 4523

May 14, 2015
Eisai Co., Ltd.

For Inquiries:

<http://www.eisai.com/>

Contents

1. Consolidated Statement of Income	-----	1
2. Capital Expenditures, Depreciation and Amortization	-----	2
3. Segment Information	-----	2
4. Financial Results by Reporting Segment	-----	3
5. Revenue from Major Products	-----	7
6. Sales Forecasts by Reporting Segment	-----	9
7. Consolidated Statement of Comprehensive Income	-----	10
8. Consolidated Statement of Cash Flows	-----	11
9. Consolidated Statement of Financial Position	-----	12
10. Changes in Quarterly Results	-----	14
	-----	17
12. Stock Information	-----	19
13. Number of Employees	-----	20
14. Major R&D Pipeline	-----	21

Currency Exchange Rates

		US (JPY/USD)	EU (JPY/EUR)	UK (JPY/GBP)	China (JPY/RMB)
	Yearly Average	83.10	107.14	131.13	13.25
	Year End Rate	94.05	120.73	143.16	15.16
	Yearly Average	100.23	134.36	159.44	16.41
	Year End Rate	102.92	141.65	171.31	16.59
FY 2014	Yearly Average	109.92	138.77	176.79	17.73
	Year End Rate	120.17	130.32	178.07	19.36
FY 2015	Forecast Rate	120.00	137.00	183.00	19.20

* The Eisai Group decided to voluntarily adopt the International Financial Reporting Standards following the FY 2013 consolidated financial statements, and in line with this change, the consolidated financial statements from Q1 of FY2014 are disclosed according to IFRS.

* The Group's business is comprised of pharmaceutical business and other business. The pharmaceutical business conducted in each region is presented as reporting segments in this report. As of the third quarter of this fiscal year,

* All amounts are rounded to the nearest specified unit.

1. Consolidated Statement of Income

(billions of yen)

	FY 2013		FY 2014				FY 2015	
	Full year	Ratio (%)	Full year	Ratio (%)	YOY (%)	Diff.	Full year (est.)	Ratio (%)
Revenue	599.5	100.0	548.5	100.0	91.5	(51.0)	556.5	100.0
Cost of sales	194.7	32.5	193.6	35.3	99.5	(1.1)	196.0	35.2
Gross profit	404.8	67.5	354.9	64.7	87.7	(50.0)	360.5	64.8
Selling, general and administrative expenses	203.3	33.9	194.5	35.5	95.7	(8.8)	188.0	33.8
Selling expenses	78.9	13.2	70.7	12.9	89.6	(8.2)		
Personnel expenses	74.2	12.4	78.4	14.3	105.7	4.2		
Administrative and other expenses	50.2	8.4	45.4	8.3	90.5	(4.8)		
Research and development expenses	136.3	22.7	131.9	24.1	96.8	(4.4)	126.5	22.7
Other income	4.1	0.7	1.0	0.2	24.2	(3.1)		
Other expenses	2.8	0.5	1.1	0.2	37.4	(1.8)		
Operating profit	66.4	11.1	28.3	5.2	42.7	(38.1)	46.0	8.3
Financial income	1.8	0.3	2.4	0.4	135.9	0.6		
Financial costs	5.9	1.0	4.9	0.9	83.1	(1.0)		
Profit before income taxes	62.3	10.4	25.9	4.7	41.5	(36.4)	42.8	7.7
Income taxes	23.8	4.0	(17.6)	(3.2)		(41.4)		
Profit for the year	38.5	6.4	43.5	7.9	112.9	5.0	27.0	4.9
Attributable to								
Owners of the parent	38.3	6.4	43.3	7.9	113.1	5.0		
Non-controlling interests	0.3	0.0	0.2	0.0	79.7	(0.1)		

Comprehensive income for the year	84.5	14.1	114.2	20.8	135.2	29.7
-----------------------------------	------	------	-------	------	-------	------

Earnings per share (EPS, yen)	134.1	151.6	93.8
Dividends per share (DPS, yen)	150.0	150.0	150.0
Return on equity (ROE, %)	7.6	7.7	4.5
Dividend on equity ratio (DOE, %)	8.5	7.6	7.2
Overseas revenue ratio(%)	40.8	43.9	

*Full year estimation for selling, general and administrative expenses includes other income and other expenses

Notes

Revenue	Growth in global brands (Halaven, Fycompa, BELVIQ) Decrease due to LOE of Aciphex in the U.S., Japanese drug price revisions and intensifying market competition
Cost of sales ratio	Increase due to change in the product mix
Selling, general and administrative expenses	Decrease in alliance fees paid to co-promotion partners Optimization of costs through promotion of organizational reform Proactive investment in global brands and in Asia and strategic markets
Research and development expenses	Upfront payment received upon the execution of options related to joint development Proactive investment in acceleration of product creation (R&D)
Profit for the year	Decrease in tax expenses incurred in Japan and the U.S.
Exchange rate effects	Revenue: 18.7 billion yen, operating profit: -3.9 billion yen
Exchange rate sensitivity (annual effect of a 1 yen depreciation in currency value)	Revenue (U.S. dollars: 1.16 billion yen, Euro: 220 million yen, U.K. pounds: 30 million yen) Operating profit (U.S. dollars: -520 million yen, Euro: 130 million yen, U.K. pounds: -90 million yen)

2. Capital Expenditures, Depreciation and Amortization

	FY 2013		(billions of yen) FY 2015	
	Full year	Full year	Diff.	Full year (est.)
Capital expenditures	31.2	42.6	11.4	18.5
Property, plant and equipment	12.3	8.9	(3.4)	9.0
Intangible assets	18.9	33.6	14.8	9.5
Depreciation and amortization	39.9	38.9	(1.0)	35.0
Property, plant and equipment	15.7	13.9	(1.8)	13.5
Intangible assets	24.2	25.1	0.8	21.5

3. Segment Information

4. Financial Results by Reporting Segment

1) Japan Pharmaceutical Business

(billions of yen)

	FY 2013	FY 2014	
	Full year	Full year	YOY (%)
Revenue	311.0	278.4	89.5
Prescription medicines	281.6	245.5	87.2
Generics (Elmed Eisai Co., Ltd.)	23.4	26.9	114.8
Diagnostics (EIDIA Co., Ltd.)	6.0	6.0	100.0
Segment profit	154.4	121.5	78.7
Japan prescription medicines - revenue from major products			
Alzheimer's disease / Dementia with Lewy bodies treatment	65.0	46.9	72.2
Aricept			
Proton-pump inhibitor	47.3	37.1	78.4
Pariet			
Fully human anti-TNF- monoclonal antibody	28.8	29.9	103.8
Humira			
Peripheral neuropathy treatment	25.2	22.4	88.8
Methycobal			

2) Americas Pharmaceutical Business (North, Central and South America)

(billions of yen)

	FY 2013	FY 2014	
	Full year	Full year	YOY (%)
Revenue	158.9	119.8	75.4 <68.8>
United States	158.3	119.0	75.2 <68.5>
Segment profit	39.1	14.9	38.1 <34.7>
Americas - revenue from major products			
Antiemetic agent Aloxi	42.9	49.8	116.1 <105.9>
United States	42.9	49.8	116.1
[Millions USD]	[428]	[453]	<105.9>
Anticancer agent Halaven	13.4	16.5	123.5 <112.9>
United States	13.1	16.0	122.7
[Millions USD]	[130]	[146]	<111.9>
Proton-pump inhibitor Aciphex	37.7	11.7	31.1 <28.4>
[Millions USD]	[376]	[107]	
Antiepileptic agent Banzel	7.6	10.4	136.4 <124.5>
United States	7.5	10.3	136.8
[Millions USD]	[75]	[94]	<124.8>
Antiobesity agent BELVIQ	2.5	5.4	215.4 <196.5>
[Millions USD]	[25]	[49]	
Antiepileptic agent Fycompa	0.8	1.9	240.9 <220.8>
United States	0.7	1.7	236.6
[Millions USD]	[7]	[16]	<215.7>
Anticancer agent Lenvima		0.4	
[Millions USD]		[3]	

* The U.S. is the only country in the Americas where Eisai markets Aciphex, BELVIQ and Lenvima.

* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

5) EMEA Pharmaceutical Business (Europe, the Middle East, Africa and Oceania)

	FY 2013	FY 2014	
	Full year	Full year	YOY (%)
Revenue	32.0	38.5	120.5 <115.8>
Segment profit	4.1	6.6	159.2 <157.6>

5. Revenue from Major Products

1) Oncology-Related Products

	FY 2013	FY 2014	
	Full year	Full year	YOY (%)
Total	100.7	98.6	97.9 <90.9>
Halaven (Anticancer agent)	28.8	35.3	122.6 <115.6>
Japan	6.4	6.1	94.4
Americas	13.4	16.5	123.5 <112.9>
Asia	0.5	1.2	239.3 <220.1>
EMEA	8.5	11.6	135.8 <129.8>
Lenvima (Anticancer agent)		0.4	
Aloxi (Antiemetic agent)	42.9	49.8	116.1 <105.9>
Treakisym/Symbenda (Anticancer agent)	3.9	3.7	95.5 <95.0>
Other	25.1	9.4	37.4 <35.1>

2) Epilepsy Products

	FY 2013	FY 2014	
	Full year	Full year	YOY (%)
Total	24.1	31.7	131.2 <123.3>
Fycompa (Antiepileptic agent)	2.1	4.3	206.8 <193.1>
Americas	0.8	1.9	240.9 <220.8>
EMEA	1.3	2.4	185.5 <175.7>
Inovelon/Banzel (Antiepileptic agent)	9.7	12.9	132.7 <122.4>
Americas	7.6	10.4	136.4 <124.5>
EMEA	1.9	2.1	111.5 <106.8>
Zonegran (Antiepileptic agent)	9.1	10.2	111.5 <106.0>
EMEA			

3) Pariet/Aciphex (Proton-pump inhibitor)

(billions of yen)

	FY 2013	FY 2014	
	Full year	Full year	YOY (%)
Total	91.4	56.0	61.2 <59.6>
Japan	47.3	37.1	78.4
Americas	37.7	11.7	31.1 <28.4>
China	2.2	2.9	129.1 <119.5>
Asia	3.5	3.7	105.6 <98.7>

* The revenue for Pariet in Japan includes the revenue for triple formulation packs for *Helicobacter pylori* eradication, Rabecure Pack 400/800 and Rabefine Pack.

* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

4) Aricept (Alzheimer's disease / Dementia with Lewy bodies treatment)

(billions of yen)

	FY 2013	FY 2014	
	Full year	Full year	YOY (%)
Total	82.7	65.7	79.4 <77.5>
Japan	65.1	47.0	72.2
China	3.8	4.7	122.8 <113.6>
Asia	8.1	9.4	115.2 <104.6>

* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan.

6. Sales Forecasts by Reporting Segment (FY 2015)

		(billions of yen)	
		FY 2014	FY 2015
		Full year	Full year (est.)
Japan		278.4	282.0
<hr/>			
	Prescription medicines	245.5	246.0
	Alzheimer's disease / Dementia with Lewy bodies treatment		
	Aricept	46.9	42.0
	Fully human anti-TNF- monoclonal antibody		
	Humira	29.9	34.0
	Proton-pump inhibitor		
	Pariet	37.1	33.0
	Peripheral neuropathy treatment		
	Methycobal	22.4	21.0
	Anticancer agent		
	Halaven	6.1	10.0
	Insomnia treatment		
	Lunesta	4.5	8.5
	Oral anticoagulant		
	Warfarin	8.6	8.0
	Osteoporosis treatment		
	Actonel	6.7	6.5
	Gastritis / Gastric ulcer treatment		
	Selbex	4.7	4.0
	Generics (Elmed Eisai Co., Ltd.)	26.9	30.0
	Diagnostics (EIDIA Co., Ltd.)	6.0	6.0
Americas		119.8	102.0
	United States	119.0	100.0
China		41.0	50.0
Asia		30.9	35.0
EMEA		38.5	45.0
Consumer Healthcare Business - Japan (mainly OTC products)		17.0	17.5
	Vitamin B2 preparation, "Chocola BB Plus," etc.		
	Chocola BB Group	10.3	10.0
Other		22.8	25.0
Consolidated revenue		548.5	556.5
	Global revenue from major products		
	Aricept	65.7	61.0
	Pariet/Aciphex	56.0	46.5
	Halaven	35.3	47.0
	Japan	6.1	10.0
	Americas	16.5	19.5
	Asia	1.2	1.8
	EMEA	11.6	15.7
	Fycompa	4.3	10.0
	Americas	1.9	5.4
	Asia	0.0	0.1
	EMEA	2.4	4.5

7. Consolidated Statement of Comprehensive Income

(billions of yen)

	FY 2013	FY 2014		
	Full year	Full year	YOY (%)	Diff.
Profit for the year	38.5	43.5	112.9	5.0
Other comprehensive income				
Items that will not be reclassified to profit or loss				
Financial assets measured at fair value through other comprehensive income	3.8	3.4	87.9	(0.5)
Remeasurements of defined benefit plans	2.5	5.0	195.0	2.4
Subtotal	6.4	8.3	130.6	2.0
Items that may be reclassified subsequently to profit or loss				
Exchange differences on translation of foreign operations	38.8	61.9	159.7	23.2
Cash flow hedges	0.8	0.5	61.1	(0.3)
Subtotal	39.6	62.4	157.6	22.8
Total other comprehensive income, net of tax	46.0	70.8	153.9	24.8
Comprehensive income for the year	84.5	114.2	135.2	29.7
Attributable to				
Owners of the parent	84.3	113.9	135.2	29.7
Non-controlling interests	0.2	0.3	115.3	0.0

8. Consolidated Statement of Cash Flows

	FY 2013	(billions of yen)	
		FY 2014	
	Full year	Full year	Diff.
Operating activities			
Profit before income taxes	62.3	25.9	(36.4)
Depreciation and amortization			

9. Consolidated Statement of Financial Position

<Assets>

(billions of yen)

Assets

Non-current assets

Property, plant and equipment

<Equity and Liabilities >

(billions of yen)

Equity

Equity attributable to owners of the parent

Share capital	45.0	4.6	45.0	4.3	100.0	
Capital surplus	57.9	6.0	58.0	5.5	100.2	0.1
Treasury shares	(38.5)	(4.0)	(37.3)	(3.5)	97.0	1.2
Retained earnings	379.2	38.9	388.0	36.8	102.3	8.8
Other components of equity	82.7	8.5	145.1	13.8	175.5	62.4
Total equity attributable to owners of the parent	526.3	54.0	598.7	56.8	113.8	72.4
Non-controlling interests	3.1	0.3	3.3	0.3	107.4	0.2
Total equity	529.4	54.4	602.1	57.1	113.7	72.7

Liabilities

Non-current liabilities

Bonds and borrowings	195.7	20.1	205.8	19.5	105.2	10.1
Other financial liabilities	2.6	0.3	2.4	0.2	89.3	(0.3)
Retirement benefit liabilities	15.5	1.6	7.2	0.7	46.7	(8.3)
Provisions	1.1	0.1	1.2	0.1	104.6	0.1
Other liabilities	27.7	2.8	25.5	2.4	92.1	(2.2)
Deferred tax liabilities	0.3	0.0	0.5	0.0	151.2	0.2
Total non-current liabilities	243.1	25.0	242.7	23.0	99.8	(0.4)

Current liabilities

Bonds and borrowings	51.5	5.3	30.2	2.9	58.7	(21.3)
Trade and other payables	62.2	6.4	84.6	8.0	135.9	22.4
Other financial liabilities	5.1	0.5	4.6	0.4	89.7	(0.5)
Income tax payables	3.9	0.4	3.9	0.4	99.1	(0.0)
Provisions	13.0	1.3	11.1	1.1	85.4	(1.9)
Other liabilities	65.5	6.7	74.6	7.1	113.9	9.1
Total current liabilities	201.3	20.7	209.1	19.8	103.8	7.7
Total liabilities	444.4	45.6	451.8	42.9	101.7	7.3
Total equity and liabilities	973.8	100.0	1,053.8	100.0	108.2	80.0

Notes

Total equity

Increase in foreign currency translation differences a

10. Changes in Quarterly Results

1) Income Statement

(billions of yen)

	FY 2013							
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Revenue	152.8	151.6	140.7	154.4	132.8	136.2	139.4	140.0
Cost of sales	46.2	47.1	54.2	47.2	48.1	45.7	49.3	50.5
Gross profit	106.6	104.5	86.5	107.2	84.7	90.5	90.1	89.5
Selling, general and administrative expenses	50.6	50.8	50.4	51.5	47.2	47.5	48.7	51.1
Selling expenses	21.8	23.1	15.4	18.6	16.8	18.6	15.6	19.7
Personnel expenses	18.4	17.7	18.8	19.3	19.3	18.4	20.4	20.3
Administrative and other expenses	10.4	10.0	16.2	13.6	11.0	10.5	12.7	11.2
Research and development expenses	37.3	30.5	35.7	32.9	29.1	33.0	35.8	34.0
Other income	0.3	3.4	0.1	0.2	0.2	0.4	0.3	0.1
Other expenses	0.4	0.3	0.3	1.7	0.1	0.9	0.1	(0.0)
Operating profit	18.6	26.3	0.2	21.3	8.5	9.6	5.8	4.5
Financial income	0.7	0.3	0.5	0.3	0.6	0.3	0.6	0.9
Financial costs	1.6	1.4	1.4	1.4	1.3	1.3	1.1	1.2
Profit before income taxes	17.7	25.2	(0.7)	20.1	7.7	8.6	5.3	4.2
Income taxes	5.3	7.0	1.9	9.6	2.0	3.8	(21.0)	(2.4)
Profit for the period	12.3	18.2	(2.5)	10.5	5.7	4.8	26.3	6.6

3) Cash Flows

(billions of yen)

	FY 2013				FY 2014			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Cash flow from operating activities	14.6	29.1	20.8	26.9	7.9	29.2	4.0	34.9
Cash flow from investing activities	26.8	(8.5)	(6.5)	9.1	(4.1)	(9.0)	(13.1)	7.3
Cash flow from financing activities	(82.2)	(5.8)	(7.9)	(19.3)	(28.7)	(3.3)	(1.4)	(26.3)
Cash and cash equivalents at the end of period	108.3	122.8	140.9	153.9	127.1	155.6	159.2	173.3
Free cash flow	2.8	29.0	12.1	35.5	4.7	24.3	(0.5)	31.9

* "Free cash flow" = "Net cash provided by (used in) operating activities" - "Capital expenditures (cash basis)"

4) Financial Positions

(billions of yen)

	June 30, 2013	September 30, 2013	December 31, 2013	March 31, 2014	June 30, 2014	September 30, 2014	December 31, 2014	March 31, 2015
Total assets	962.6	974.2	1,007.6	973.8	938.6	969.9	1,050.2	1,053.8
Equity	495.0	513.5	524.4	529.4	507.4	542.6	590.7	602.1
Attributable to owners of the parent	491.2	510.5	521.4	526.3	504.3	539.5	587.5	598.7
Liabilities	467.5	460.8	483.2	444.4	431.2	427.3	459.5	451.8
Bonds	30.0	30.0	30.0	30.0	30.0	30.0	30.0	30.0
Borrowings	227.4	221.6	227.2	217.3	211.0	210.3	233.2	206.1
Commercial paper			10.0					
Ratio of equity attributable to owners of the parent (%)	51.0	52.4	51.7	54.0	53.7	55.6	55.9	56.8
Liabilities ratio (Net DER / times)	0.29	0.22	0.20	0.14	0.18	0.11	0.11	0.06

* "Liabilities ratio (Net DER)" = ("Interest-bearing debt" ("Bonds and borrowings") - "Cash and cash equivalents" -

"Time deposits exceeding three months, etc.") / "Equity attributable to owners of the parent"

5) Changes in Quarterly Revenue from Major Products

(1) Oncology-Related Products

	FY 2013							
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Total	27.1	26.6	23.6	23.4	24.2	22.6	25.8	26.0
Halaven (Anticancer agent)	6.9	6.9	7.5	7.5	8.2	8.3	9.3	9.5
Japan	1.6	1.6	1.7	1.5	1.6	1.4	1.6	1.5
Americas	3.3	3.2	3.4	3.4	3.8	3.8	4.3	4.5
Asia	0.1	0.1	0.2	0.2	0.2	0.3	0.3	0.4

11. Trends in Financial Results (IFRS)

	FY 2012 Full year	FY 2013 Full year	FY 2014 Full year
<Income statement data>			
Revenue	572.6	599.5	548.5
Cost of sales	176.3	194.7	193.6
Selling, general and administrative expenses	197.1	203.3	194.5
Research and development expenses	119.3	136.3	131.9
Other income	1.3	4.1	1.0
Other expenses	0.8	2.8	1.1
Operating profit	80.4	66.4	28.3
Profit for the year	51.9	38.5	43.5
Comprehensive profit for the year	101.9	84.5	114.2

<Values for Reference Trends in Financial Results (J-GAAP)>

(billions of yen)

	FY2005	FY2006	FY2007	FY2008	FY2009	FY2010	FY2011	FY2012	FY2013
<Income statement data>									
Net sales	601.3	674.1	734.3	781.7	803.2	768.9	648.0	573.7	600.4
Cost of sales	104.5	109.3	118.8	152.5	160.7	167.8	173.4	174.1	188.2
R&D expenses	93.2	108.3	225.4	156.1	179.1	145.0	125.1	120.4	130.5
SG&A expenses	307.8	351.2	372.3	381.4	376.9	343.0	253.7	208.7	210.5
Operating income	95.7	105.3	17.7	91.8	86.4	113.1	95.7	70.5	71.1
Ordinary income	100.0	110.5	18.9	82.6	79.7	105.2	90.0	65.6	64.9
Net income (loss)	63.4	70.6	(17.0)	47.7	40.3	67.4	58.5	48.3	33.0
Cash income		97.6	106.9	119.0	126.4	120.0	107.7	100.7	83.6
<Cash flow statement data>									
Net cash provided by (used in) operating activities	87.1	81.2	73.2	105.0	107.9	123.2	90.6	73.2	85.7
Net cash provided by (used in) investing activities	(29.5)	(55.2)	(476.4)	(55.0)	(69.8)	(58.8)	(2.6)	21.7	26.2
Net cash provided by (used in) financing activities	(21.8)	(40.6)	375.4	(31.0)	(49.2)	(68.0)	(78.0)	(81.8)	(114.8)
Free cash flow	43.6	28.6	(415.9)	59.3	52.9	100.3	71.4	54.5	66.4
<Balance sheet data>									
Common stock	45.0	45.0	45.0	45.0	45.0	45.0	45.0	45.0	45.0
Total assets	747.2	792.1	1,123.9	1,148.2	1,101.9	1,046.3	1,004.7	990.2	945.5
Shareholders' equity	519.2	552.5	448.9	428.0	415.9	404.2	416.8	469.4	506.8
<Capital expenditures and Depreciation/Amortization>									
Capital expenditures	37.0	52.0	434.0	47.3	28.7	23.7	20.7	20.5	25.6
Depreciation and amortization	25.0	26.8	34.6	49.1	48.9	43.5	41.7	43.3	39.1
<Managerial indices>									
Dividend payment (billions of yen)	25.7	34.1	37.0	39.9	42.7	42.7	42.7	42.8	42.8
Dividends on equity (DOE, %)	5.3	6.4	7.4	9.1	10.1	10.4	10.4	9.6	8.8
Dividend payout ratio (DPR, %)	40.6	48.4	-	83.7	105.9	63.4	73.1	88.6	129.8
Return on sales ratio (%)	10.5	10.5	(2.3)	6.1	5.0	8.8	9.0	8.4	5.5
Return on equity (ROE, %)	13.0	13.2	(3.4)	10.9	9.6	16.4	14.3	10.9	6.8
Return on assets (ROA, %)	9.0	9.2	(1.8)	4.2	3.6	6.3	5.7	4.8	3.4
Total capital turnover ratio (no. of times)	0.9	0.9	0.8	0.7	0.7	0.7	0.6	0.6	0.6
Shareholders' equity ratio (%)	69.5	69.7	39.9	37.3	37.7	38.6	41.5	47.4	53.6
Liabilities ratio (Net DER / times)	-	-	0.64	0.63	0.62	0.49	0.38	0.27	0.14
Leverage (times)	1.4	1.4	2.5	2.7	2.6	2.6	2.4	2.1	1.9
Earnings per share (EPS, yen)	221.9	247.8	(59.8)	167.3	141.6	236.5	205.3	169.4	115.6
Diluted EPS (yen)	221.6	247.5	-	167.3	141.6	236.5	205.3	169.3	115.5
Cash EPS (yen)		342.7	375.8	417.8	443.7	421.3	377.8	353.5	293.1
Cash dividends per share (yen)	90.0	120.0	130.0	140.0	150.0	150.0	150.0	150.0	150.0
Price-book value ratio (PBR, times)	2.8	2.9	2.2	1.9	2.3	2.1	2.2	2.6	2.3
Treasury stock purchase (thousand shares)	-	2,000	-	-	-	-	-	-	-
Treasury stock purchase (billions of yen)	-	11.1	-	-	-	-	-	-	-
Number of consolidated subsidiaries	40	45	63	50	49	50	48	48	47

* "Cost of sales" includes "Provision for (reversal of) sales returns-net."

* "Free cash flow" = "Net cash provided by (used in) operating activities" - "Capital expenditures (cash basis)"

* "Diluted EPS" for FY2009 onwards has been calculated in accordance with new accounting standards.

* "Depreciation and amortization" includes amortization of "Intangible assets." The definition was partially changed in FY2008.

* "Cash income" = "Net income (loss)" + "Depreciation of PP&E and amortization of intangible assets" + "In-process R&D expenses" + "Amortization of goodwill" + "Loss on impairment of long-lived assets (including loss on devaluation of investment securities)"

* In accordance with the partial change in definition of "Cash income" and "Cash EPS", results for the previous year have been amended.

* "Cash EPS (Cash income per share)" = "Cash income" / "Average number of outstanding shares for the period (after deduction of treasury stock)"

* "Liabilities ratio (Net DER)" = ("Interest-bearing debt" ("Borrowings" + "Bonds and debentures") - "Cash and cash in banks" - "Short-term investments") / "Shareholders' equity"

* "Leverage" = "Total assets" / "Shareholders' equity"

12. Stock Information

1) Number of Shares Issued and Shareholders

As of March 31, 2015

Total Number of
Authorized Shares
(shares)
1,100,000,000

2) Top 10 Shareholders

As of March 31, 2015

JPMorgan Chase Bank 385147

* Treasury stock (10,869 thousand shares, 3.67%) has been excluded as it has no voting rights.

* Number of shares has been rounded down to the nearest thousand.


3) Number of Shareholders by Category

185	0.2	163	0.2	(22)
56	0.1	41	0.1	(15)
1,075	1.0	906	1.4	(169)
545	0.5	577	0.9	32
105,119	98.3	64,502	97.4	(40,617)
1	0.0	1	0.0	0
106,981	100.0	66,190	100.0	(40,791)

4) Number of Shares Held by Category

(1,000 shares)

14. Major R&D Pipeline



	AF	(JP) approved	Vascular and Immunological Reaction
		(CN) approved	Gastrointestinal and Hepatic Disorders
Preparing for Submission			
		(EU/AS) submitted	Oncology and Supportive Care
	AI	(US/EU) submitted	Neurology
	AI	(JP) submitted	Oncology and Supportive Care
	AI	(CN) submitted	Neurology
Clinical (Phase II or later)			
		(CN) PIII	Oncology and Supportive Care

Fycompa (Partial-onset seizure) fBT/TT6 1 Tf7.02 0 0 7.02 66.36 462.2003 Tm0 Tc0 Tw@003F/TT2 1 Tf1.4188 .0427 TD-.0012 Tc.0054 Tw[(Lenvy)11.6(ima (Hepat)-5

(1) Oncology and Supportive Care

Development Code: **E7389** Generic Name: **eribulin** Product Name: **Halaven**

Indications / Drug class: Anticancer agent / microtubule dynamics inhibitor		In-house		
Description A synthetic analog of halichondrin B derived from the marine sponge, <i>Halichondria okadai</i> . Shows an antitumor effect by arresting the cell cycle through inhibition of the growth of microtubules. Currently being investigated as a potential treatment for various other solid tumors. Approved in 58 countries including in the United States, European Union (EU), Japan and Asia for breast cancer. Also approved in Europe as a second-line treatment for breast cancer in June 2014. Currently approved as a second-line treatment in 40 countries.				
Second-line treatment for breast cancer (Additional Indication)	Study 301	EU: approved (June 2014)		Inj.
Third-line treatment for breast cancer	304	CN: PIII	Submission Target: FY2015	Inj.
First-/second-line treatment for HER2-negative breast cancer (Additional Indication)	303	US: PIII		

Development progress from April 2014 onwards Development progress from January 2015 onwards

Development Code: **MORAb-004**

Indications / Drug class: Anticancer agent / humanized anti-endosialin monoclonal antibody			In-house
Description: A humanized IgG1 monoclonal antibody that targets Tumor Endothelial Marker 1 (TEM-1) / endosialin. Expected to show an antitumor effect against carcinomas that express endosialin.			
Melanoma	Study 201	US/EU: PII	Inj.
Colorectal cancer	202	US/EU: PII	Inj.
Sarcoma	203	US/EU: PII	Inj.

Development Code: **MORAb-009** Generic Name: **amatuximab**

Indications / Drug class: Anticancer agent / chimeric anti-mesothelin monoclonal antibody			In-house
Description: A chimeric IgG1 monoclonal antibody that blocks the function of mesothelin. Expected to show an antitumor effect against carcinomas that express mesothelin.			
Mesothelioma	Study 003	US/EU: PII	Inj.

Development Code: **E7820**

Indications / Drug class: Anticancer agent / alpha 2 integrin suppressant			In-house
Description: An angiogenesis inhibitor that suppresses the expression of alpha 2 integrin, a vascular endothelial cell adhesion molecule.			
Colorectal cancer	Study 702	US/EU: PII	Oral

Development Code: **E7272** Generic Name: **denileukin diftitox** Product Name: **Ontak**

(2) Neurology

Development Code: **E2020** Generic Name: **donepezil** Product Name: **Aricept**

Indications / Drug class: Treatment of dementia of the Alzheimer's type / dementia with Lewy bodies		In-house	
Description: Increases levels of the neurotransmitter acetylcholine in the brain by inhibiting its breakdown by the enzyme acetylcholinesterase, thereby slowing the overall progression of symptoms associated with Alzheimer's disease (AD). Currently approved in more than 90 countries around the world for the treatment of mild to moderate AD. It is also approved as a treatment for patients with severe AD in numerous countries including the United States, Japan, Canada, and several other Asian and Latin American countries. Also approved in Japan for dementia with Lewy bodies in September 2014.			
Dementia with Lewy bodies (Additional Indication)	Study 341	JP: approved (September 2014)	Oral
Severe Alzheimer's disease (Additional Indication)	339	CN: Submitted (February 2015)	Oral
Regression symptoms in people with Down syndrome (Additional Indication)	345	JP: PII	Oral
Transdermal formulation (E2022, Additional Formulation)		JP: PI	(Collaboration with Teikoku Pharmaceuticals) Patch

Regarding the higher dose (23 mg) formulation which previously had a submission target of FY2014, a Phase III study conducted in Japan did not meet its primary endpoint. Upon receiving these results, the Company decided to discontinue development of the higher dose formulation for Japan.

Development Code: **E2007** Generic Name: **perampanel** Product Name: **Fycompa**

Indications / Drug class: Antiepileptic agent / AMPA receptor antagonist		In-house	
Description: A selective antagonist against the AMPA receptor (a glutamate receptor subtype). Approved as an adjunctive therapy for partial-onset seizures in 45 countries including in Europe, the United States, and Canada.			
Partial-onset seizures	Study 335	JP/CN/AS: PIII	Submission Target: FY2015 Oral
Primary generalized tonic-clonic seizures (Additional Indication)	332	US: submitted (August 2014), accepted (October 2014) EU: submitted (August 2014), accepted (September 2014) JP/AS: PIII	Oral Submission Target: FY2015
Pediatric partial-onset seizures (Additional Indication)	232	US/EU: PII	Oral

Simultaneous submission for primary generalized tonic-clonic seizures and partial-onset seizures in Japan is scheduled for FY2015.

Development Code: **E0302** Generic Name: **mecobalamin**

Indications / Drug class: Amyotrophic lateral sclerosis (ALS)		In-house	
Description: A mecobalamin (vitamin B ₁₂ coenzyme) formulation. Restores damaged peripheral nerves and the active component is widely used for the treatment of peripheral neuropathy. Currently being investigated as a potential treatment for amyotrophic lateral sclerosis (ALS).			
Amyotrophic lateral sclerosis (ALS)	Study 761/762	JP: PII/III	Submission Target: FY2015 Inj.

Submission target has been revised from FY2014 to FY2015

Development Code: **E2080** Generic Name: **rufinamide** Product Name: **Inovelon/Banzel**

Indications / Drug class: Antiepileptic agent		In-license (Novartis)	
Description: A triazole derivative that is structurally unrelated to currently marketed antiepileptic drugs (AEDs). The agent is believed to exert its antiepileptic effects by regulating activity of voltage-gated sodium channels in the brain involved in the overexcitement of neurons that potentially causes seizures, so as to prolong their inactive state. Currently approved in Japan, Europe and the United States as an adjunctive therapy to other AEDs in the treatment of Lennox-Gastaut syndrome (LGS), one of the most severe and intractable forms of childhood-onset epilepsy. The product names are Inovelon in Japan and Europe and Banzel in the United States.			
Pediatric Lennox-Gastaut syndrome (LGS) (Additional Indication)	Study 303	US approved (February 2015)	Oral

Development progress from April 2014 onwards Development progress from January 2015 onwards

Development Code: **BAN2401**

Development progress from April 2014 onwards Development progress from January 2015 onwards

Reference Data [R&D Pipeline] 25

May 14, 2015 / Eisai Co., Ltd.

(3) Vascular and Immunological Reaction

Generic Name: **flecainide** Product Name: **Tambocor**

Indications / Drug class: Anti-tachyarrhythmia agent	In-house
Description: Suppresses tachyarrhythmia by blocking cardiac sodium channels. The agent was approved for the treatment of tachyarrhythmia (paroxysmal atrial fibrillation/flutter and ventricular tachycardia) in adults and tachyarrhythmia (paroxysmal atrial fibrillation/flutter, paroxysmal supraventricular tachycardia and ventricular tachycardia) in pediatric patients.	
Fine granule formulation (Additional Formulation)	JP: approved (February 2015) Oral.

Development Code: **E5501/AKR-501** Generic Name: **avatrombopag**

Indications / Drug class: Treatment for thrombocytopenia / thrombopoietin receptor agonist	In-house
Description: A novel, oral thrombopoietin receptor agonist that stimulates platelet production. Expected to show effects against conditions that are associated with thrombocytopenia.	
Thrombocytopenia in chronic liver disease requiring surgery	Study 310/311 JP/US/EU/AS: PIII Oral
Idiopathic thrombocytopenic purpura (ITP)	302 US/EU/AS: PIII Oral
Thrombocytopenia during interferon therapy (both initiation and maintenance) for hepatitis C	203 US: PII Oral

Japan was added to the global Phase III clinical study of thrombocytopenia in chronic liver disease requiring surgery. Furthermore, the submission target was revised from FY2015 to FY2017.

Development Code: **E6005**

Indications / Drug class: Anti-atopic dermatitis / Phosphodiesterase 4 inhibitor	In-house
Description: Inhibits the activity of phosphodiesterase 4, a cyclic AMP-degrading enzyme that acts as an intracellular messenger. Expected to be effective as a treatment to suppress the various symptoms associated with atopic disease.	
Atopic dermatitis	Study 102 JP: PII Topical

Development Code: **E6011**

Autoimmune disorder/Inflammatory diseases (anti Fractalkine antibody)	PI/II	In-house	Inj.
---	-------	----------	------

Development Code: **MORAb-022**

Rheumatoid arthritis (antibody)	PI	In-house	Inj.
---------------------------------	----	----------	------

Development Code: **E6007**

Activated integrin inhibitors	PI	In-house	Oral.
-------------------------------	----	----------	-------

Development progress from April 2014 onwards Development progress from January 2015 onwards

(4) Gastrointestinal and Hepatic Disorders

Development Code: **E3810** Generic Name: **rabeprazole** Product Name: **Pariet/Aciphex**

Indications / Drug class: Proton pump inhibitor

In-house

Description: A proton pump inhibitor approved for the treatment of gastric and duodenal ulcers, reflux esophagitis, eradication of *Helicobacter pylori* infections and triple formulation packs (combination packs) for H. pylori eradication which contain rabeprazole, etc.